Ernexa Therapeutics Inc.ERNANASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank14
Year-over-Year Change
Year-over-year SG&A expense growth
Percentile
P14
Within normal range
vs 5Y Ago
-6.2x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -29.82% |
| Q2 2025 | -3.94% |
| Q1 2025 | -7.73% |
| Q4 2024 | -54.45% |
| Q3 2024 | -13.22% |
| Q2 2024 | 3.23% |
| Q1 2024 | -16.25% |
| Q4 2023 | 13.24% |
| Q3 2023 | 53.63% |
| Q2 2023 | -27.90% |
| Q1 2023 | -2.81% |
| Q4 2022 | 10.63% |
| Q3 2022 | -38.51% |
| Q2 2022 | 20.36% |
| Q1 2022 | 8.43% |
| Q4 2021 | -1.68% |
| Q3 2021 | -7.57% |
| Q2 2021 | 182.26% |
| Q1 2021 | 192.25% |
| Q4 2020 | -48.77% |
| Q3 2020 | 4.83% |
| Q2 2020 | -1.84% |
| Q1 2020 | 0.00% |